STOCK TITAN

KalVista Pharmaceuticals, Inc. - KALV STOCK NEWS

Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.

KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).

KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:

  • Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
  • Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.

The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.

KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.

Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.

Rhea-AI Summary

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has provided an operational update alongside its financial results for the second fiscal quarter ended October 31, 2021. The company is initiating a Phase 3 clinical trial for KVD900 and enrolling patients in the KVD824 Phase 2 KOMPLETE trial. Significant progress includes the confirmation of trial designs by the FDA and positive Phase 2 results for KVD900. However, the company reported a net loss of $19.7 million, with no revenue generated during the quarter, and increased R&D and G&A expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
-
Rhea-AI Summary

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the grant of inducement options for 18,000 shares to six newly-hired employees, effective December 1, 2021. The options have an exercise price of $13.63 per share, aligned with the closing stock price on the grant date. Vesting occurs over four years: one-fourth after one year, with remaining shares vesting monthly over three years. This move complies with Nasdaq Listing Rule 5635(c)(4) and is part of KalVista's strategy to attract talent for its innovative therapies targeting hereditary angioedema and diabetic macular edema.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.1%
Tags
none
-
Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) has completed a positive End-of-Phase 2 meeting with the FDA regarding its clinical trial for KVD900, an oral treatment for hereditary angioedema (HAE). The company expects to initiate its Phase 3 trial in Q1 2022, with positive results from previous trials supporting the trial design. The Phase 3 trial will recruit approximately 100 patients across over 50 sites worldwide, aiming to evaluate symptom relief times, including severe HAE attacks. KalVista is well-capitalized, expected to fund operations until early 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
Rhea-AI Summary

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its participation in two upcoming investor conferences:

  • Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 9:20 a.m. EST
  • Jefferies London Healthcare Conference on November 16, 2021, at 5:40 p.m. GMT

Live webcasts of the presentations will be available on www.kalvista.com, with archives accessible for 30 days post-event. KalVista focuses on small molecule protease inhibitors for unmet medical needs, including therapies for hereditary angioedema and diabetic macular edema.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
conferences
-
Rhea-AI Summary

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presented Phase 2 data for KVD900 at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. KVD900 is an oral treatment for hereditary angioedema (HAE) that demonstrated rapid absorption, with significant symptom relief observed faster than placebo (1.6 hours vs 9.0 hours, p<0.0001). The findings suggest KVD900 could significantly improve patient outcomes during HAE attacks. The data also indicates strong agreement between Patient Global Impression of Change and other reported outcomes, underscoring its clinical relevance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
Rhea-AI Summary

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced that its compensation committee granted inducement options to purchase 23,000 shares of common stock to six newly-hired employees on November 3, 2021. The options have an exercise price of $18.22 per share, equal to the closing price on the grant date. Vesting occurs over four years, with one-fourth vesting on the first anniversary and the rest monthly over three years. KalVista focuses on developing small molecule protease inhibitors for unmet medical needs, specifically targeting HAE and DME.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) announced on October 1, 2021, the grant of inducement options to six newly-hired employees, allowing them to purchase a total of 40,000 shares of common stock at an exercise price of $17.33, which matches the stock's closing price on the grant date. The options will vest over four years, with one-fourth vesting on the one-year anniversary and the remainder vesting monthly thereafter. These grants comply with Nasdaq Listing Rule 5635(c)(4), highlighting KalVista's commitment to incentivizing new talent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
Rhea-AI Summary

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced participation in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 8:40 a.m. ET. A live webcast will be accessible on their website, with an audio archive available for 30 days post-event. KalVista focuses on developing small molecule protease inhibitors for unmet medical needs, with significant products like KVD900 for hereditary angioedema (HAE) and KVD001 for diabetic macular edema (DME) in clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
conferences
-
Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) has announced the lifting of the clinical hold on its Phase 2 trial for KVD824, intended for the oral prophylactic treatment of hereditary angioedema (HAE). The FDA's approval allows the company to initiate U.S. site activities for the KOMPLETE trial, which aims to enroll 48 patients across 30 sites in 13 countries. Previous studies indicated KVD824 maintained necessary plasma concentrations with no serious adverse events reported. The trial's primary endpoint focuses on the rate of HAE attacks during treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
Rhea-AI Summary

KalVista Pharmaceuticals (KALV) announced operational progress and financial results for the fiscal quarter ending July 31, 2021. They are advancing the Phase 2 KOMPLETE clinical trial for KVD824 and have scheduled an FDA End-of-Phase 2 meeting for KVD900, aiming to initiate a Phase 3 study soon. Financially, the company reported no revenue, increased R&D expenses of $13.7 million, and a net loss of $16.1 million. Cash reserves decreased to $230.6 million, primarily due to higher operating costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.89%
Tags

FAQ

What is the current stock price of KalVista Pharmaceuticals (KALV)?

The current stock price of KalVista Pharmaceuticals (KALV) is $9.03 as of January 3, 2025.

What is the market cap of KalVista Pharmaceuticals (KALV)?

The market cap of KalVista Pharmaceuticals (KALV) is approximately 443.3M.

What does KalVista Pharmaceuticals specialize in?

KalVista Pharmaceuticals specializes in the discovery, development, and commercialization of small molecule protease inhibitors.

What diseases does KalVista target with its products?

KalVista targets hereditary angioedema (HAE) and diabetic macular edema (DME) with its products.

What is a plasma kallikrein inhibitor?

A plasma kallikrein inhibitor is a type of medication that blocks the action of plasma kallikrein, which plays a role in conditions like HAE and DME.

Where does KalVista Pharmaceuticals operate?

KalVista Pharmaceuticals operates primarily in the United States.

How can investors stay updated on KalVista's progress?

Investors can stay updated through KalVista's official website and stock market platforms like StockTitan.

Has KalVista formed any strategic partnerships?

Yes, KalVista has formed several strategic partnerships to advance its research and development efforts.

What are KalVista's recent achievements?

Recent achievements include successful clinical trials, securing funding, and strategic partnerships.

What is hereditary angioedema (HAE)?

Hereditary angioedema (HAE) is a disorder characterized by severe swelling in various parts of the body.

What is diabetic macular edema (DME)?

Diabetic macular edema (DME) is a complication of diabetes that affects the retina and can lead to vision loss.

What financial condition is KalVista in?

KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments.
KalVista Pharmaceuticals, Inc.

Nasdaq:KALV

KALV Rankings

KALV Stock Data

443.28M
43.78M
1.36%
110.29%
14.98%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE